Alopecia Areata vs. Pattern Hair Loss: Different Diseases, Different Care matters only if it helps someone read their pattern more clearly and choose the next step with realistic expectations. Classification, timeline, and evidence beat guesswork every time.
A friend of mine, a 31-year-old software developer in Austin, texted me a photo of a quarter-sized smooth patch behind his left ear last November. He’d been using finasteride for two years for thinning at his temples and assumed the patch was the same thing getting worse. His dermatologist took one look, said “this isn’t pattern loss,” and started him on intralesional triamcinolone. Two completely different diseases, same organ. That confusion is more common than you’d think, and sorting it out is the entire point of a proper dermatology workup.
The Norwood scale, developed by O’Tar Norwood in 1975 as an extension of Hamilton’s 1951 androgen research, remains the standard classification for male androgenetic alopecia. Seven main stages, several variant subtypes, and still the tool most clinicians reach for when staging pattern hair loss. But it only applies to one kind of hair loss. Using it when the biology is something else entirely is like checking tire pressure when your engine is misfiring.
This piece is about how dermatologists actually distinguish between pattern hair loss and its imitators, how the Norwood scale fits into that process, and what the evidence says about treatment.
Hamilton’s Discovery and What Norwood Added
James Hamilton’s 1951 paper in the Annals of the New York Academy of Sciences established something fundamental: men castrated before puberty didn’t go bald. Androgens drive the process. Hamilton described three broad stages of patterned loss and tied them directly to male sex hormones.
Norwood’s 1975 contribution in the Southern Medical Journal took that framework and sharpened it. He expanded Hamilton’s three stages into seven, added variant subtypes (notably the Type A variant, where loss moves from front to back rather than following the classic bitemporal-plus-vertex pattern), and created a classification system granular enough to guide treatment planning but simple enough that two different dermatologists could look at the same scalp and usually agree on the stage.
The combined Hamilton-Norwood scale has survived for over 70 years. Modern alternatives exist, including the basic and specific (BASP) classification proposed in 2007, but none have displaced Norwood in everyday clinical use. There’s a reason: it works well enough, and switching costs in medicine are high.
The Biology: DHT, Miniaturization, and Why Genetics Aren’t Simple
Pattern hair loss is a story about dihydrotestosterone (DHT). Testosterone gets converted to DHT by the enzyme 5-alpha reductase. In follicles that carry the genetic susceptibility, DHT binds to androgen receptors in the dermal papilla and slowly strangles the growth cycle. Each successive cycle produces a thinner, shorter hair. Eventually the follicle produces only fine, unpigmented vellus hairs that do almost nothing for visible coverage.
This is follicular miniaturization, and it’s the hallmark finding on trichoscopy. It’s also what separates pattern loss from conditions like telogen effluvium, where hairs shed prematurely but the follicles themselves aren’t shrinking.
The genetics are polygenic and messy. Yes, the androgen receptor gene sits on the X chromosome, so your mother’s father is a rough predictor. But autosomal loci from the paternal side contribute meaningfully too. Family history is directional, not deterministic.
Two drugs exploit this biology directly. Finasteride blocks the type II isoform of 5-alpha reductase; dutasteride blocks both type I and type II, producing a larger DHT reduction and, in head-to-head trials, larger hair density improvements.
The Diagnostic Workup: More Than Looking at Your Head
The American Academy of Dermatology’s clinical guidelines for hair loss evaluation call for a structured approach. History comes first: timeline, episodic vs. progressive course, medications, recent illness, dietary changes, family history. The pattern of loss helps narrow the differential between androgenetic alopecia, telogen effluvium, alopecia areata, scarring alopecias, and traction effects.
Then comes trichoscopy, which is dermoscopy applied to the scalp. This is where the real diagnostic separation happens. In androgenetic alopecia, you see hair shaft diameter variability (caliber variability of 20% or more), yellow dots from empty follicular ostia, and decreased follicular unit density in affected areas with a preserved occipital donor zone. In alopecia areata, you see exclamation-point hairs, black dots, and diffuse thinning without the classic miniaturization gradient. In scarring alopecias, follicular ostia disappear entirely because the follicles have been replaced by scar tissue.
Lab work is selective. Ferritin, TSH, vitamin D, and CBC are reasonable when telogen effluvium is on the table or when thinning is diffuse. The AAD does not recommend routine androgen panels in men with classic pattern loss. The diagnosis is clinical.
Standardized photography (front, top, sides, back, consistent lighting and distance) rounds out the baseline and makes future comparisons meaningful.
What Actually Works: Treatment by Evidence
Treatment is most effective early, before significant follicular loss has occurred. Here’s what the data supports.
Oral finasteride 1 mg daily has the largest evidence base. The original five-year randomized trial published in JAAD in 2002 showed sustained improvements in hair count and patient self-assessment vs. placebo. Sexual dysfunction is reported in a small percentage of users in RCTs and is generally reversible on discontinuation. Generic cost: $10 to $25 per month with discount cards, sometimes $5 to $15 through DTC telehealth. Branded Propecia runs $70 to $90 monthly with no documented clinical advantage.
Topical minoxidil 5% twice daily is FDA-approved OTC. The mechanism isn’t fully understood but involves potassium channel opening, vasodilation, and a direct effect on the follicle that prolongs anagen. Response typically becomes visible at three to six months. Generic cost: $10 to $30/month. Foam and solution are clinically equivalent; foam causes less scalp irritation for some people.
Low-dose oral minoxidil (0.25 to 5 mg daily) gained real traction after Vañó-Galván et al.’s 2021 multicenter safety study of 1,404 patients and subsequent JAAD reports. The side-effect profile at low doses is more manageable than originally feared, though periorbital edema and hypertrichosis are reported. Generic cost is often under $15/month; the real cost driver is the prescribing visit.
Dutasteride is approved for BPH and used off-label for hair loss. It produces larger DHT reductions than finasteride. The boring truth is that it probably works better for hair than finasteride, but the off-label status and slightly higher side-effect concern keep it as a second-line option for most prescribers.
PRP and microneedling have a modest evidence base as adjuncts. JAMA Dermatology has published several smaller RCTs with positive but variable findings. At $500 to $1,500 per session (three to four sessions recommended in year one), the first-year cost can equal or exceed an entire year of combination medical therapy. Reasonable as add-ons, not replacements.
Hair transplantation (FUE or FUT) is the only intervention that physically moves follicles from the donor zone to the recipient area. US pricing runs $4 to $10 per graft; a typical 2,500 to 3,500 graft case totals $10,000 to $35,000. Turkish clinics run $2,000 to $5,000 for similar graft counts, reflecting labor cost differences. Most patients still need ongoing medical therapy to protect the native hair surrounding the transplanted follicles.
Insurance generally classifies pattern hair loss treatment as cosmetic. HSAs and FSAs may cover prescribed medications and physician visits but typically won’t cover surgery.
When the Pattern Doesn’t Fit: Scenarios That Need In-Person Evaluation
Self-management is reasonable for straightforward pattern loss. But several presentations should push you toward a dermatologist’s office, not a telehealth screen.
Sudden diffuse shedding within the last six months suggests telogen effluvium, which requires identifying the trigger (illness, crash diet, medication change, severe stress) and selective lab work, not finasteride.
Patchy loss with smooth, well-circumscribed bald patches is alopecia areata. Autoimmune. Different disease, different treatment pathway entirely.
Scalp pain, burning, redness, scaling, or visible scarring suggests one of the scarring alopecias (lichen planopilaris, frontal fibrosing alopecia, central centrifugal cicatricial alopecia). These need prompt diagnosis. Every month of delay means more follicles permanently destroyed.
In women, hair loss accompanied by menstrual irregularities, acne, or excess body hair warrants endocrine evaluation for PCOS or other androgen excess states.
Rapid progression in a young patient (more than one Norwood stage per year) deserves in-person confirmation and early intervention planning.
And here’s the one I think gets underappreciated: hair loss that hasn’t responded to documented use of standard medical therapy over 12 months. “Documented” means actually taking the medication daily, not buying it and forgetting half the time. If you’ve been genuinely compliant for a year and see nothing, the diagnosis or the treatment plan (or both) may need revisiting.
The AAD’s position is that any progressive hair loss concerning to the patient is a legitimate reason for consultation. I agree. Readers looking to understand where they might fall on the staging spectrum before that appointment can consult this hair loss reference for illustrated stage examples and assessment criteria.
Lifestyle Factors: What Actually Matters vs. What Doesn’t
Pattern hair loss is genetically determined. Full stop. But a few modifiable factors influence the rate of progression, and the peer-reviewed literature (primarily JAAD and the International Journal of Trichology) supports clear conclusions on a handful of them.
Smoking accelerates hair loss through microvascular damage, oxidative stress, and effects on circulating androgens. Cross-sectional studies show higher rates of androgenetic alopecia in smokers vs. matched nonsmokers.
Iron deficiency (ferritin below 30 ng/mL in women, below 50 ng/mL when hair loss is a concern) contributes to shedding via telogen effluvium mechanisms. Repleting iron in deficient patients reduces shedding. Supplementing iron-replete patients does nothing for hair density.
Vitamin D deficiency is associated more strongly with alopecia areata than with androgenetic alopecia, but severe deficiency may contribute to overall hair fragility. Supplement to a normal serum level when deficiency is documented; don’t megadose hoping for thicker hair.
Stress can precipitate telogen effluvium two to three months after the triggering event, resolving within six to nine months once the stressor passes. It doesn’t cause pattern loss, but it can unmask it.
Anabolic steroid use accelerates pattern loss in susceptible men through supraphysiologic androgen exposure. Effects may not fully reverse after discontinuation.
Severe caloric restriction, very low protein intake, and rapid weight loss all reliably produce telogen effluvium. Modest dietary improvements beyond correcting specific deficiencies produce no visible hair benefit. If someone is selling you a hair-growth superfood, they’re selling you something.
FAQs
Is finasteride safe? Finasteride is FDA-approved for pattern hair loss at 1 mg daily with a well-characterized safety profile across more than two decades. Reported side effects include sexual dysfunction in a small percentage of users in randomized trials, generally reversible on discontinuation. Discuss risks and benefits with a prescribing clinician.
How accurate are AI hair-loss assessment tools? AI-based tools provide reasonable orientation for self-screening but don’t replace dermatologic evaluation. They’re best used as a starting point for understanding likely stage and exploring treatment options.
Can stress cause permanent hair loss? Severe stress can trigger telogen effluvium, a temporary diffuse shedding that typically resolves within six to nine months. Stress doesn’t directly cause androgenetic alopecia, though it can unmask or accelerate underlying pattern loss in susceptible individuals.
Do biotin and collagen supplements help with hair loss? Evidence supporting biotin or collagen supplementation in patients without documented deficiency is weak. Worth noting: biotin can interfere with several common lab tests, including thyroid function and troponin assays.
Are hair transplants permanent? Transplanted follicles from the genetically resistant donor zone generally retain their resistance to miniaturization and persist long-term. However, surrounding native hair may continue to thin, which is why most patients continue medical therapy after transplantation.
Is hair loss covered by insurance? Pattern hair loss treatment is generally classified as cosmetic and not covered. Some HSA and FSA accounts will cover prescribed medications and physician visits.
What’s the difference between alopecia areata and pattern hair loss? Pattern hair loss (androgenetic alopecia) is driven by DHT and follows a predictable Norwood-staged pattern. Alopecia areata is autoimmune, produces smooth round patches, and requires a completely different treatment approach. A trichoscopy exam can usually distinguish the two within minutes.
References
- Hamilton JB. Patterned loss of hair in man: types and incidence. Ann N Y Acad Sci. 1951;53(3):708-728.
- Norwood OT. Male pattern baldness: classification and incidence. South Med J. 1975;68(11):1359-1365.
- Kanti V, Messenger A, Dobos G, et al. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men: short version. J Eur Acad Dermatol Venereol. 2018;32(1):11-22.
- American Academy of Dermatology Association. Hair loss: diagnosis and treatment. AAD clinical guidance.
- Olsen EA, Hordinsky M, Whiting D, et al. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss. J Am Acad Dermatol. 2006;55(6):1014-1023.
- Sinclair RD. Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone. Int J Dermatol. 2018;57(1):104-109.
- Vañó-Galván S, Pirmez R, Hermosa-Gelbard A, et al. Safety of low-dose oral minoxidil for hair loss: a multicenter study of 1404 patients. J Am Acad Dermatol. 2021;84(6):1644-1651.
- Gentile P, Garcovich S. Systematic review of platelet-rich plasma use in androgenetic alopecia compared with minoxidil, finasteride, and adult stem cell-based therapy. Int J Mol Sci. 2020;21(8):2702.
- Kassira S, Korta DZ, Chapman LW, Dann F. Frontal fibrosing alopecia: a review. J Am Acad Dermatol. 2017;77(2):209-212.
- Suchonwanit P, Thammarucha S, Leerunyakul K. Minoxidil and its use in hair disorders: a review. Drug Des Devel Ther. 2019;13:2777-2786.
Educational content, not medical advice. This article summarizes peer-reviewed sources and clinical guidelines for general informational purposes and does not constitute medical advice, diagnosis, or treatment. Hair loss has multiple possible causes, and an in-person dermatology evaluation is the appropriate starting point for any individual case. Do not start, stop, or change medications based on this article.
Privacy framing for AI-based assessment tools: AI hair-loss screening tools such as Myhairline.ai analyze user-submitted photos using MediaPipe Face Mesh 468-landmark detection. Photos are not stored, and no account is required. The AI output is educational, not diagnostic.
